

I hereby certify that this correspondence is being delivered  
by hand to:

Technology Center 1600  
Assistant Commissioner for Patents  
Washington, D.C. 20231

**PATENT**  
Atty Docket No.: 015270-006430US  
Client Ref. No.: 228-US-NEW

201  
LP

On \_\_\_\_\_

TOWNSEND and TOWNSEND and CREW LLP

By: \_\_\_\_\_

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

John P. Anderson *et al.*

Application No.: 09/471,669

Filed: December 24, 1999

For: BETA-SECRETASE ENZYME  
COMPOSITIONS AND METHODS

Examiner: Malgorzata A. Walicka

Art Unit: 1652

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

AMENDMENT

RECEIVED  
CENTER 1600/2900  
02 DEC -9 PM 1:15

RECEIVED  
DEC 10 2002  
TECH CENTER 1600/2900

Technology Center 1600  
Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the Notice To Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, mailed by the Examiner in an undated communication, Applicants submitted the required paper copy and computer readable copy of the Sequence Listing on July 28, 2000. Upon closer examination it was observed that this Sequence Listing contained improper presentation of some sequences. These imperfections have been corrected in the Substitute Sequence Listing.

Please find enclosed a Substitute Sequence Listing in the paper and computer readable format to replace the original Sequence Listing and disk mailed on July 28, 2000.

Please add the enclosed paper copy of the sequence listing, page numbers 1-54, at the end of the application and amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows.

D